Docstoc
EXCLUSIVE OFFER FOR DOCSTOC USERS
Try the all-new QuickBooks Online for FREE.  No credit card required.

New European Medical Device Regulations recognize to reduce potential delays

Document Sample
New European Medical Device Regulations recognize to reduce potential delays Powered By Docstoc
					Proposed Changes in the European Medical Device Directive 2012/0266
(COD): A Practical Approach to the New Regulations
This EU MDD webinar will help you understand and recognize the most significant changes proposed
for the new European Medical Device Regulations: 2012/0266 (COD). You will learn which procedural
changes your company should be making now so that you stay in compliance throughout the
transition period and reduce potential delays to new product introductions in the EU market.


Description


Why Should You Attend:


The M5 version of the MDD (i.e. – the 2007/47/EC amendment to 93/42/EEC), implemented on March
21st of 2010, resulted in minor and major nonconformities throughout the medical device industry
during annual Notified Body audits. The 2007/47/EC amendment reclassified some high-risk devices
from to Class III devices and the amendment made Clinical Evaluations mandatory for all products
(i.e. – Essential Requirement 6a). For some companies, it took more two years to achieve compliance.
These were minor changes when compared to the 2012/0266 proposed regulation. These proposed
regulations are approximately twice as long as both of the previous directives (MDD & AIMD)
combined.


Learning about these changes and understanding how the changes will affect your company will allow
companies to revise and update their policies and procedures prior to the implementation period. A
better understanding of the changes will avoid unnecessary nonconformities and delays to new
product introductions in Europe.


This course has been designed to help you understand and recognize the most significant changes
proposed for the new European Medical Device Regulations: 2012/0266 (COD). You will learn which
procedural changes your company should be making now so that you stay in compliance throughout
the transition period and reduce potential delays to new product introductions in the EU market.


Areas Covered in this Session:


This webinar will provide valuable assistance to all medical device companies in evaluating their
anticipated CE Marking applications and any supplemental changes. The focus will be on practical
approaches for addressing the proposed changes in the Medical Device Regulations for Europe—
released September 26, 2012. Critical changes with significant impact include:


   1. device classifications.
   2. clinical investigation requirements.
   3. clinical evaluation requirements.
   4. UDI implementation and implant cards.
   5. role of economic operators.
   6. Notified Body (NB) selection.
   7. Medical Device Coordination Group (MDCG).
   8. vigilance & post-market surveillance requirements.
   9. post-market clinical follow-up studies.
   10. sources of post-market data.


Who Will Benefit:


This topic applies to personnel / companies in the medical device industry. The employees who will
benefit most include:


       Senior management
       Regulatory affairs
       Quality Assurance
       Engineering / R&D
       New product development teams
       Marketing and Sales
       Product Packaging and labeling
       Suppliers to medical device companies


Instructor Profile:


Robert Packard, is a regulatory consultant with 20 years experience in the medical device,
pharmaceutical and biotechnology industries. Robert has worked with companies from start-ups to
Fortune 100, in the USA, Canada, Mexico and Japan. His specialty is helping companies with
regulatory submissions for high-risk medical devices and drug/device combination products. His
regulatory expertise includes: CE Marking, Canadian Medical Device Applications, 510(k) Submissions,
Post-Marketing Activities, Supplier Quality, CAPA, Risk Management, Auditing and Sterilization
Validation. He has held previous positions in R&D, Manufacturing Operations, Quality Assurance and
Regulatory Affairs—up to the level of CEO/President. In addition, Robert has extensive technical
experience in Lean Manufacturing, Silicone Chemistry, Extrusion, Bioprocess Engineering, and
Strategic Planning. He was a 3rd party auditor for one of the largest Notified Bodies, and he conducts
training workshops internationally on a variety of regulatory subjects. Robert is a graduate of UConn
in Chemical Engineering.

				
DOCUMENT INFO
Description: M5 version of the MDD and 2007/47/EC amendment reclassified high-risk devices from to Class III devices and made Clinical Evaluations mandatory. All medical device companies in evaluating their CE Marking applications with UDI implementation and sources of post-market data.